AIKI
Get informed when a big investor buys or sells
+ FollowUndervalued by 65.6% based on the discounted cash flow analysis.
| Market cap | $81.01 Million |
|---|---|
| Enterprise Value | $71.54 Million |
| Dividend Yield | $- (42.92%) |
| Earnings per Share | $-1.57 |
| Beta | 0 |
| Outstanding Shares | 22,754,753 |
| P/E Ratio | -0.49 |
|---|---|
| PEG | 0.37 |
| Price to Sales | 0.71 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 0.54 |
| Enterprise Value to EBIT | 0.85 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.22 |
| Debt to Equity | 0.71 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
No data
AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology company with a diverse portfolio of small-molecule anti-cancer therapeutics. The Company's platform consists of patented technology from leading universities and res...